Published in J Virol on October 01, 2002
Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest (2007) 1.88
Nucleocapsid protein function in early infection processes. Virus Res (2008) 1.53
CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J Virol (2003) 1.17
Importin-beta family members mediate alpharetrovirus gag nuclear entry via interactions with matrix and nucleocapsid. J Virol (2006) 1.09
Rubella virus capsid protein modulates viral genome replication and virus infectivity. J Virol (2004) 1.01
NC-mediated nucleolar localization of retroviral gag proteins. Virus Res (2012) 0.87
Cytoplasmic utilization of human immunodeficiency virus type 1 genomic RNA is not dependent on a nuclear interaction with gag. J Virol (2012) 0.86
Nuclear trafficking of retroviral RNAs and Gag proteins during late steps of replication. Viruses (2013) 0.85
Comparative analysis of RNA/protein dynamics for the arginine-rich-binding motif and zinc-finger-binding motif proteins encoded by HIV-1. Biophys J (2010) 0.79
Investigating the cellular distribution and interactions of HIV-1 nucleocapsid protein by quantitative fluorescence microscopy. PLoS One (2015) 0.76
Orchestrating the Selection and Packaging of Genomic RNA by Retroviruses: An Ensemble of Viral and Host Factors. Viruses (2016) 0.76
Induced degradation of Tat by nucleocapsid (NC) via the proteasome pathway and its effect on HIV transcription. Viruses (2013) 0.75
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (1988) 220.77
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell (1987) 12.30
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
A quantitative assay for HIV DNA integration in vivo. Nat Med (2001) 8.67
Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein. Cell (1991) 8.31
HIV-1 gag proteins: diverse functions in the virus life cycle. Virology (1998) 7.32
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci U S A (1991) 4.66
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell (1995) 4.25
Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues. EMBO J (1994) 2.86
Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A (1991) 2.81
Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J Virol (1996) 2.75
Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science (1996) 2.42
Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses. J Virol (1992) 2.36
HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro. Proc Natl Acad Sci U S A (1996) 2.30
Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. J Virol (1999) 2.13
Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J (1995) 2.10
Structural biology of HIV. J Mol Biol (1999) 2.03
Zinc finger structures in the human immunodeficiency virus type 1 nucleocapsid protein facilitate efficient minus- and plus-strand transfer. J Virol (2000) 1.88
The role of nucleocapsid of HIV-1 in virus assembly. Virology (1998) 1.84
Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J Virol (1991) 1.74
Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin. J Virol (1999) 1.57
Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. J Biol Chem (1999) 1.27
Involvement of HIV-I nucleocapsid protein in the recruitment of reverse transcriptase into nucleoprotein complexes formed in vitro. J Biol Chem (1998) 1.26
Promoter activity of Tat at steps subsequent to TATA-binding protein recruitment. Mol Cell Biol (1997) 1.02
The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry. Virology (1998) 0.89
Enhancement of the basal-level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein. Virology (2000) 0.82
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67
Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest (2007) 1.88
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr (2009) 1.83
Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog (2009) 1.25
Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution. Cell Res (2010) 0.88
Absence of exposure to varicella does not increase the risk of zoster. Clin Infect Dis (2011) 0.85
New anti-HSV therapeutics target the helicase-primase complex. Nat Med (2002) 0.82
A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study. J Infect Dis (2003) 0.79
Cocaine enhances myocarditis induced by encephalomyocarditis virus in murine model. Am J Physiol Heart Circ Physiol (2002) 0.78
Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol (2005) 0.77
Mixed glycoprotein B genotypes of cytomegalovirus and immunosuppression. Clin Infect Dis (2004) 0.75
Use of antiviral drugs to prevent herpesvirus transmission. N Engl J Med (2004) 0.75
Valganciclovir and human herpesvirus-8. J Infect Dis (2008) 0.75